You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Cardiovascular
Moderna Inks Supply Agreement with Peru for 20m Doses of Its COVID-19 Vaccine
24 September 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) has inked a supply agreement with the government of Peru for 20 m doses of Moderna's COVID-19 vaccine to begin delivery in the first quarter of 2022, the company said.
The COVID-19 Vaccine Moderna is not currently approved for use in Peru, and the company will work with regulators to pursue necessary approvals prior to distribution.
Moderna's mRNA platform builds on advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein. On December 18, 2020, the US FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older.
Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing from the World Health Organization.
The COVID-19 Vaccine Moderna is not currently approved for use in Peru, and the company will work with regulators to pursue necessary approvals prior to distribution.
Moderna's mRNA platform builds on advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein. On December 18, 2020, the US FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older.
Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing from the World Health Organization.
Login
Related Headlines
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal